Record Revenue Growth
Total revenues for the 2025 fiscal year were $84 million, a $27.9 million increase or 52% over the prior year.
Significant Profit Increase
Operating income for 2025 was $19.6 million, an increase of 82% from the previous fiscal year.
Successful Product Launch
Launch of the Lisdexamfetamine product line in the last quarter contributed significantly to revenue growth, capturing about 8-10% of the market despite high competition.
Positive Cash Flow
Operating cash flow was positive at $7.5 million, compared to a $3.2 million cash burn the previous year, marking a $10.7 million swing to the positive.
Strengthened Balance Sheet
Working capital increased to $45.9 million from $27 million, and current liabilities decreased, indicating low and decreasing debt.